Embree Financial Group Buys 64 Shares of Eli Lilly and Company (NYSE:LLY)

Embree Financial Group increased its stake in Eli Lilly and Company (NYSE:LLY) by 9.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 775 shares of the company’s stock after buying an additional 64 shares during the quarter. Embree Financial Group’s holdings in Eli Lilly and Company were worth $687,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. International Assets Investment Management LLC lifted its position in shares of Eli Lilly and Company by 9.2% during the first quarter. International Assets Investment Management LLC now owns 13,757 shares of the company’s stock worth $10,463,000 after purchasing an additional 1,160 shares during the last quarter. Unique Wealth LLC bought a new stake in shares of Eli Lilly and Company during the first quarter worth $260,000. Salem Investment Counselors Inc. lifted its position in shares of Eli Lilly and Company by 2.8% during the first quarter. Salem Investment Counselors Inc. now owns 72,338 shares of the company’s stock worth $56,276,000 after purchasing an additional 1,961 shares during the last quarter. Contravisory Investment Management Inc. bought a new stake in shares of Eli Lilly and Company during the first quarter worth $501,000. Finally, Cooper Financial Group lifted its position in shares of Eli Lilly and Company by 16.1% during the first quarter. Cooper Financial Group now owns 1,521 shares of the company’s stock worth $1,183,000 after purchasing an additional 211 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $917.97 on Friday. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The company has a market cap of $872.44 billion, a PE ratio of 135.19, a P/E/G ratio of 2.79 and a beta of 0.42. The business has a 50-day simple moving average of $921.21 and a two-hundred day simple moving average of $858.02. Eli Lilly and Company has a fifty-two week low of $547.61 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, equities analysts expect that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LLY has been the subject of several research analyst reports. Citigroup initiated coverage on Eli Lilly and Company in a research report on Friday, September 13th. They set a “buy” rating and a $1,060.00 target price for the company. BMO Capital Markets raised their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Jefferies Financial Group raised their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Truist Financial raised their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Finally, JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $986.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.